Testosterone Therapy for the Treatment of Age-Related Hypogonadism: Risks with Uncertain Benefits

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Pharmacology

Background:

• Testosterone replacement therapy (TRT) has been FDA-approved since the 1950s for men with "classical" hypogonadism, characterized by specific endocrine conditions.
• A growing population of aging men with low serum testosterone, often with comorbidities, are receiving TRT despite not having "classical" hypogonadism.

Purpose of the Study:

• To evaluate the established indications and controversial uses of testosterone replacement therapy.
• To assess the benefits and risks of TRT in aging men with "age-related hypogonadism" compared to "classical" hypogonadism.

Main Methods:

• Review of FDA-approved indications for testosterone products.
• Analysis of the risks and benefits associated with testosterone use in different patient populations.
• Examination of clinical evidence regarding TRT in aging men with low testosterone levels.

Main Results:

• TRT is approved for "classical" hypogonadism stemming from hypothalamic, pituitary, or testicular dysfunction.
• The benefits of TRT in aging men with low testosterone ("age-related hypogonadism") are uncertain.
• TRT carries risks, including potential major adverse cardiac events and increased blood pressure, which can elevate risks of myocardial infarction and stroke.

Conclusions:

• TRT is not FDA-approved for "age-related hypogonadism" due to uncertain clinical benefits and known/potential adverse outcomes.
• The use of TRT in aging men with low testosterone requires careful consideration of risks versus uncertain benefits.
• Physicians must weigh the established efficacy for "classical" hypogonadism against the controversial and potentially risky application in older men.